Radium-223

<p>Radium-223  (223Ra, Ra-223) is an <a href="/facts/Isotopes_of_radium/T0SlGtRH">isotope</a> of <a href="/facts/Radium/VWo5gkzn">radium</a> with an 11.4-day <a href="/facts/Half-life/kGVH8BAB">half-life</a>. It was discovered in 1905 by T. Godlewski, a Polish chemist from <a href="/facts/Krak%25C3%25B3w/hubj59IT">Kraków</a>, and was historically known as <a href="/facts/Decay_chain/JvTwPNBn">actinium X</a> (AcX). Radium-223 dichloride is an alpha particle-emitting radiotherapy drug that mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover. The principal use of radium-223, as a <a href="/facts/Radiopharmaceutical/x3g6zbB6">radiopharmaceutical</a> to treat <a href="/facts/Metastasis/4dadbm6z">metastatic</a> cancers in <a href="/facts/Bone/pCU37jBe">bone</a>, takes advantage of its chemical similarity to <a href="/facts/Calcium/hf252CC0">calcium</a>, and the short range of the <a href="/facts/Alpha_radiation/dzNMs9WP">alpha radiation</a> it emits.
</p>

Radium-223 open-in-new

Radium-223